Cargando…

Development and validation of a novel online calculator for estimating survival benefit of adjuvant transcatheter arterial chemoembolization in patients undergoing surgery for hepatocellular carcinoma

BACKGROUND AND AIMS: Although adjuvant transcatheter arterial chemoembolization (TACE) for resected hepatocellular carcinoma (HCC) may improve survival for some patients, identifying which patients can benefit remains challenging. The present study aimed to construct a survival prediction calculator...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Lei, Li, Chao, Wang, Ming-Da, Wang, Hong, Zhou, Ya-Hao, Zeng, Yong-Yi, Zhang, Wan-Guang, Chen, Ting-Hao, Wang, Nan-Ya, Li, Jie, Zhang, Yao-Ming, Wang, Yu, Gu, Wei-Min, Xing, Hao, Diao, Yong-Kang, Lau, Wan Yee, Zhang, Cheng-Wu, Pawlik, Timothy M., Shen, Feng, Huang, Dong-Sheng, Yang, Tian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8507320/
https://www.ncbi.nlm.nih.gov/pubmed/34641921
http://dx.doi.org/10.1186/s13045-021-01180-5
_version_ 1784581830811320320
author Liang, Lei
Li, Chao
Wang, Ming-Da
Wang, Hong
Zhou, Ya-Hao
Zeng, Yong-Yi
Zhang, Wan-Guang
Chen, Ting-Hao
Wang, Nan-Ya
Li, Jie
Zhang, Yao-Ming
Wang, Yu
Gu, Wei-Min
Xing, Hao
Diao, Yong-Kang
Lau, Wan Yee
Zhang, Cheng-Wu
Pawlik, Timothy M.
Shen, Feng
Huang, Dong-Sheng
Yang, Tian
author_facet Liang, Lei
Li, Chao
Wang, Ming-Da
Wang, Hong
Zhou, Ya-Hao
Zeng, Yong-Yi
Zhang, Wan-Guang
Chen, Ting-Hao
Wang, Nan-Ya
Li, Jie
Zhang, Yao-Ming
Wang, Yu
Gu, Wei-Min
Xing, Hao
Diao, Yong-Kang
Lau, Wan Yee
Zhang, Cheng-Wu
Pawlik, Timothy M.
Shen, Feng
Huang, Dong-Sheng
Yang, Tian
author_sort Liang, Lei
collection PubMed
description BACKGROUND AND AIMS: Although adjuvant transcatheter arterial chemoembolization (TACE) for resected hepatocellular carcinoma (HCC) may improve survival for some patients, identifying which patients can benefit remains challenging. The present study aimed to construct a survival prediction calculator for individualized estimating the net survival benefit of adjuvant TACE for patients with resected HCC. METHODS: From a multicenter database, consecutive patients undergoing curative resection for HCC were enrolled and divided into the developing and validation cohorts. Using the independent survival predictors in the developing cohort, two nomogram models were constructed for patients with and without adjuvant TACE, respectively, which predictive performance was validated internally and externally by measuring concordance index (C-index) and calibration. The difference between two estimates of the prediction models was the expected survival benefit of adjuvant TACE. RESULTS: A total of 2514 patients met the inclusion criteria for the study. The nomogram prediction models for patients with and without adjuvant TACE were, respectively, built by incorporating the same eight independent survival predictors, including portal hypertension, Child–Pugh score, alpha-fetoprotein level, tumor size and number, macrovascular and microvascular invasion, and resection margin. These two prediction models demonstrated good calibration and discrimination, with all the C-indexes of greater than 0.75 in the developing and validation cohorts. A browser-based calculator was generated for individualized estimating the net survival benefit of adjuvant TACE. CONCLUSIONS: Based on large-scale real-world data, an easy-to-use online calculator can be adopted as a decision aid to predict which patients with resected HCC can benefit from adjuvant TACE. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13045-021-01180-5.
format Online
Article
Text
id pubmed-8507320
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-85073202021-10-20 Development and validation of a novel online calculator for estimating survival benefit of adjuvant transcatheter arterial chemoembolization in patients undergoing surgery for hepatocellular carcinoma Liang, Lei Li, Chao Wang, Ming-Da Wang, Hong Zhou, Ya-Hao Zeng, Yong-Yi Zhang, Wan-Guang Chen, Ting-Hao Wang, Nan-Ya Li, Jie Zhang, Yao-Ming Wang, Yu Gu, Wei-Min Xing, Hao Diao, Yong-Kang Lau, Wan Yee Zhang, Cheng-Wu Pawlik, Timothy M. Shen, Feng Huang, Dong-Sheng Yang, Tian J Hematol Oncol Letter to the Editor BACKGROUND AND AIMS: Although adjuvant transcatheter arterial chemoembolization (TACE) for resected hepatocellular carcinoma (HCC) may improve survival for some patients, identifying which patients can benefit remains challenging. The present study aimed to construct a survival prediction calculator for individualized estimating the net survival benefit of adjuvant TACE for patients with resected HCC. METHODS: From a multicenter database, consecutive patients undergoing curative resection for HCC were enrolled and divided into the developing and validation cohorts. Using the independent survival predictors in the developing cohort, two nomogram models were constructed for patients with and without adjuvant TACE, respectively, which predictive performance was validated internally and externally by measuring concordance index (C-index) and calibration. The difference between two estimates of the prediction models was the expected survival benefit of adjuvant TACE. RESULTS: A total of 2514 patients met the inclusion criteria for the study. The nomogram prediction models for patients with and without adjuvant TACE were, respectively, built by incorporating the same eight independent survival predictors, including portal hypertension, Child–Pugh score, alpha-fetoprotein level, tumor size and number, macrovascular and microvascular invasion, and resection margin. These two prediction models demonstrated good calibration and discrimination, with all the C-indexes of greater than 0.75 in the developing and validation cohorts. A browser-based calculator was generated for individualized estimating the net survival benefit of adjuvant TACE. CONCLUSIONS: Based on large-scale real-world data, an easy-to-use online calculator can be adopted as a decision aid to predict which patients with resected HCC can benefit from adjuvant TACE. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13045-021-01180-5. BioMed Central 2021-10-12 /pmc/articles/PMC8507320/ /pubmed/34641921 http://dx.doi.org/10.1186/s13045-021-01180-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Letter to the Editor
Liang, Lei
Li, Chao
Wang, Ming-Da
Wang, Hong
Zhou, Ya-Hao
Zeng, Yong-Yi
Zhang, Wan-Guang
Chen, Ting-Hao
Wang, Nan-Ya
Li, Jie
Zhang, Yao-Ming
Wang, Yu
Gu, Wei-Min
Xing, Hao
Diao, Yong-Kang
Lau, Wan Yee
Zhang, Cheng-Wu
Pawlik, Timothy M.
Shen, Feng
Huang, Dong-Sheng
Yang, Tian
Development and validation of a novel online calculator for estimating survival benefit of adjuvant transcatheter arterial chemoembolization in patients undergoing surgery for hepatocellular carcinoma
title Development and validation of a novel online calculator for estimating survival benefit of adjuvant transcatheter arterial chemoembolization in patients undergoing surgery for hepatocellular carcinoma
title_full Development and validation of a novel online calculator for estimating survival benefit of adjuvant transcatheter arterial chemoembolization in patients undergoing surgery for hepatocellular carcinoma
title_fullStr Development and validation of a novel online calculator for estimating survival benefit of adjuvant transcatheter arterial chemoembolization in patients undergoing surgery for hepatocellular carcinoma
title_full_unstemmed Development and validation of a novel online calculator for estimating survival benefit of adjuvant transcatheter arterial chemoembolization in patients undergoing surgery for hepatocellular carcinoma
title_short Development and validation of a novel online calculator for estimating survival benefit of adjuvant transcatheter arterial chemoembolization in patients undergoing surgery for hepatocellular carcinoma
title_sort development and validation of a novel online calculator for estimating survival benefit of adjuvant transcatheter arterial chemoembolization in patients undergoing surgery for hepatocellular carcinoma
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8507320/
https://www.ncbi.nlm.nih.gov/pubmed/34641921
http://dx.doi.org/10.1186/s13045-021-01180-5
work_keys_str_mv AT lianglei developmentandvalidationofanovelonlinecalculatorforestimatingsurvivalbenefitofadjuvanttranscatheterarterialchemoembolizationinpatientsundergoingsurgeryforhepatocellularcarcinoma
AT lichao developmentandvalidationofanovelonlinecalculatorforestimatingsurvivalbenefitofadjuvanttranscatheterarterialchemoembolizationinpatientsundergoingsurgeryforhepatocellularcarcinoma
AT wangmingda developmentandvalidationofanovelonlinecalculatorforestimatingsurvivalbenefitofadjuvanttranscatheterarterialchemoembolizationinpatientsundergoingsurgeryforhepatocellularcarcinoma
AT wanghong developmentandvalidationofanovelonlinecalculatorforestimatingsurvivalbenefitofadjuvanttranscatheterarterialchemoembolizationinpatientsundergoingsurgeryforhepatocellularcarcinoma
AT zhouyahao developmentandvalidationofanovelonlinecalculatorforestimatingsurvivalbenefitofadjuvanttranscatheterarterialchemoembolizationinpatientsundergoingsurgeryforhepatocellularcarcinoma
AT zengyongyi developmentandvalidationofanovelonlinecalculatorforestimatingsurvivalbenefitofadjuvanttranscatheterarterialchemoembolizationinpatientsundergoingsurgeryforhepatocellularcarcinoma
AT zhangwanguang developmentandvalidationofanovelonlinecalculatorforestimatingsurvivalbenefitofadjuvanttranscatheterarterialchemoembolizationinpatientsundergoingsurgeryforhepatocellularcarcinoma
AT chentinghao developmentandvalidationofanovelonlinecalculatorforestimatingsurvivalbenefitofadjuvanttranscatheterarterialchemoembolizationinpatientsundergoingsurgeryforhepatocellularcarcinoma
AT wangnanya developmentandvalidationofanovelonlinecalculatorforestimatingsurvivalbenefitofadjuvanttranscatheterarterialchemoembolizationinpatientsundergoingsurgeryforhepatocellularcarcinoma
AT lijie developmentandvalidationofanovelonlinecalculatorforestimatingsurvivalbenefitofadjuvanttranscatheterarterialchemoembolizationinpatientsundergoingsurgeryforhepatocellularcarcinoma
AT zhangyaoming developmentandvalidationofanovelonlinecalculatorforestimatingsurvivalbenefitofadjuvanttranscatheterarterialchemoembolizationinpatientsundergoingsurgeryforhepatocellularcarcinoma
AT wangyu developmentandvalidationofanovelonlinecalculatorforestimatingsurvivalbenefitofadjuvanttranscatheterarterialchemoembolizationinpatientsundergoingsurgeryforhepatocellularcarcinoma
AT guweimin developmentandvalidationofanovelonlinecalculatorforestimatingsurvivalbenefitofadjuvanttranscatheterarterialchemoembolizationinpatientsundergoingsurgeryforhepatocellularcarcinoma
AT xinghao developmentandvalidationofanovelonlinecalculatorforestimatingsurvivalbenefitofadjuvanttranscatheterarterialchemoembolizationinpatientsundergoingsurgeryforhepatocellularcarcinoma
AT diaoyongkang developmentandvalidationofanovelonlinecalculatorforestimatingsurvivalbenefitofadjuvanttranscatheterarterialchemoembolizationinpatientsundergoingsurgeryforhepatocellularcarcinoma
AT lauwanyee developmentandvalidationofanovelonlinecalculatorforestimatingsurvivalbenefitofadjuvanttranscatheterarterialchemoembolizationinpatientsundergoingsurgeryforhepatocellularcarcinoma
AT zhangchengwu developmentandvalidationofanovelonlinecalculatorforestimatingsurvivalbenefitofadjuvanttranscatheterarterialchemoembolizationinpatientsundergoingsurgeryforhepatocellularcarcinoma
AT pawliktimothym developmentandvalidationofanovelonlinecalculatorforestimatingsurvivalbenefitofadjuvanttranscatheterarterialchemoembolizationinpatientsundergoingsurgeryforhepatocellularcarcinoma
AT shenfeng developmentandvalidationofanovelonlinecalculatorforestimatingsurvivalbenefitofadjuvanttranscatheterarterialchemoembolizationinpatientsundergoingsurgeryforhepatocellularcarcinoma
AT huangdongsheng developmentandvalidationofanovelonlinecalculatorforestimatingsurvivalbenefitofadjuvanttranscatheterarterialchemoembolizationinpatientsundergoingsurgeryforhepatocellularcarcinoma
AT yangtian developmentandvalidationofanovelonlinecalculatorforestimatingsurvivalbenefitofadjuvanttranscatheterarterialchemoembolizationinpatientsundergoingsurgeryforhepatocellularcarcinoma